XSHG
600267
Market cap2.07bUSD
Oct 08, Last price
11.64CNY
Name
Zhejiang Hisun Pharmaceutical Co Ltd
Chart & performance
P/E
25.41
P/S
1.30
EPS
0.46
Div yield, %
1.79%
Shrs. gr., 5y
4.01%
Rev. gr., 5y
-1.46%
Revenues
10.55b
+7.79%
Net income
541m
-10.06%
CFO
2.03b
-3.92%
Dividend
Jun 16, 20260.21 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Hisun Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the development, manufacturing, and distribution of a broad spectrum of pharmaceutical products. Its portfolio includes both active pharmaceutical ingredients (APIs) and finished drug formulations. The company's extensive therapeutic focus spans oncology, cardiovascular health, infectious diseases, liver support, orthopedics, parasitic infections, and immunosuppression. Additionally, Hisun Pharmaceutical addresses conditions such as weight management, viral infections, tuberculosis, and offers veterinary pharmaceuticals, among other specialized medical applications. Beyond its product lines, the firm provides product consultation and contract manufacturing/research (CMO/CRO) services. Established in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is headquartered in Taizhou, China.
Key people
Weihong Xiao
Chairman of the Board, President · since 2024
Ling Jiang
Chief Financial Officer, Senior Vice President · since 2024
Hongshun Jin
Senior Vice President · since 2019
Zhiqing Yang
Senior Vice President · since 2019
Xifei Shen
Secretary of the Board · since 2017
Jiaqiu Du
Senior Vice President, Director · since 2022
Director · since 2018
Baichao Zheng
Director · since 2018
Independent Director · since 2019
Jiayi Zhao
Independent Director · since 2019
Independent Director · since 2022
Headquarters & legal address
浙江省台州市椒江区外沙路46号
台州市, ZJ 100000
CN
台州市, ZJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||